A detailed history of Jpmorgan Chase & CO transactions in Cassava Sciences Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 55,877 shares of SAVA stock, worth $1.44 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
55,877
Previous 55,874 0.01%
Holding current value
$1.44 Million
Previous $1.13 Million 39.1%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$12.35 - $26.11 $37 - $78
3 Added 0.01%
55,877 $690,000
Q1 2024

May 10, 2024

BUY
$18.44 - $26.41 $13,737 - $19,675
745 Added 1.35%
55,874 $1.13 Million
Q4 2023

Feb 12, 2024

BUY
$12.64 - $30.11 $74,904 - $178,431
5,926 Added 12.04%
55,129 $1.24 Million
Q3 2023

Nov 14, 2023

SELL
$16.64 - $25.32 $106,778 - $162,478
-6,417 Reduced 11.54%
49,203 $818,000
Q2 2023

Aug 11, 2023

BUY
$21.59 - $27.88 $129,820 - $167,642
6,013 Added 12.12%
55,620 $1.36 Million
Q1 2023

May 18, 2023

BUY
$23.46 - $36.44 $1.14 Million - $1.76 Million
48,428 Added 4107.55%
49,607 $1.2 Million
Q1 2023

May 11, 2023

SELL
$23.46 - $36.44 $895,843 - $1.39 Million
-38,186 Reduced 97.0%
1,179 $28,000
Q4 2022

Feb 13, 2023

BUY
$27.82 - $44.16 $117,928 - $187,194
4,239 Added 12.07%
39,365 $1.16 Million
Q3 2022

Nov 14, 2022

SELL
$16.33 - $51.06 $338,684 - $1.06 Million
-20,740 Reduced 37.12%
35,126 $1.47 Million
Q2 2022

Aug 11, 2022

BUY
$17.22 - $38.47 $467,488 - $1.04 Million
27,148 Added 94.53%
55,866 $1.57 Million
Q1 2022

May 11, 2022

BUY
$32.6 - $53.05 $134,409 - $218,725
4,123 Added 16.76%
28,718 $1.07 Million
Q4 2021

Feb 10, 2022

BUY
$36.77 - $90.91 $56,846 - $140,546
1,546 Added 6.71%
24,595 $1.08 Million
Q3 2021

Nov 12, 2021

BUY
$41.79 - $135.3 $963,217 - $3.12 Million
23,049 New
23,049 $1.43 Million

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $1.04B
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.